Roundtable Discussion: Novel Oral Anti-Coagulants (NOACs) 1
Published: 29 August 2023
-
Views:
55
-
Likes:
7
-
Views:
55
-
Likes:
7
-
Up Next -
Part 1 | Session 2 Test video with no video just image
Overview
On November 12th 2014, Radcliffe Cardiology, in association with the Arrhythmia & Electrophysiology Review (AER) journal, filmed a roundtable discussion entitled 'Novel Oral Anti-Coagulants (NOACs): Hot Topics & Current Issues' in London, UK.
The discussion was moderated by Professor A. John Camm (London, UK), a renowned authority in anticoagulation and atrial fibrillation, and an editorial board member of AER. He was joined by expert group of physicians including Doctor Marco Alings (Breda, NL), Professors Raffaele De Caterina (Chieti, IT), Paulus Kirchhof (Birmingham, UK), Jean-Yves Le Heuzey (Paris, FR) and Freek Verheugt (Amsterdam, NL).
The meeting comprised of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants in various clinical scenarios.
This educational activity is intended for an international audience of non-US healthcare professionals, specifically electrophysiologists and cardiologists. However, neurologists, internal medicine specialists, primary care physicians, and other healthcare professionals involved in the diagnosis and management of patients with atrial fibrillation (AF) will also find this topical.
The CME e-learning modules can be accessed here. This course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 CME credit hour.
On 12 November 2014, Radcliffe Cardiology, in association with Arrhythmia & Electrophysiology Review (AER) journal, held a roundtable discussion in London, UK. The discussion held between an expert group of physicians was moderated by Professor A John Camm, a renowned authority in anticoagulation and atrial fibrillation. The meeting comprised a series of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants (NOACs): real-world versus clinical trial data; once or twice daily dosing regimens; spot checks or monitoring for anticoagulation status; antidotes for NOACs; NOACs and dual antiplatelet therapy; NOAC treatment in chronic renal impairment; and choosing between NOACs. This paper summarises the presentations and presents key highlights from the subsequent discussions.
TEST TES TEST
TEST
More from this programme
Part 1
SESSION 1
About the episode
Faculty Biographies
Paulus Kirchhof
Director of the Institute of Cardiovascular Sciences AND Chair in Cardiovascular Medicine
Prof Kirchhof is the Director of the Institute of Cardiovascular Sciences at the University of Birmingham. Prof Kirchhof research includes novel molecular mechanisms of heart disease that can be leveraged to develop personalised treatment approaches to common cardiovascular diseases.
A John Camm
Professor of Clinical Cardiology
Professor John Camm became Professor of Clinical Cardiology at St. George’s University of London 1986. He continues to hold this positions alongside positions as Professor of Clinical Cardiology at St George’s Hospital London and Professor of Cardiology at Imperial College London.
An internationally renowned expert in atrial fibrillation (AF), Prof Camm leads the European Network for translational research in atrial fibrillation, which works towards a better understanding of AF. Other research interests include ventricular tachycardia, cardiomyopathy, pacemakers and sudden cardiac death.
Professor Camm is a Senior Consulting Editor for the European Heart Journal and Editor of the European Society of Cardiology Textbook of Cardiovascular Medicine. He has received numerous awards for his contributions to cardiology, including the British Cardiovascular Society Mackenzie Medal and the European Society of Cardiology Gold Medal.
Transcript
TEST
TEST
TEST
Comments